This study is currently not recruiting participants.

CA209153; A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Study on Adverse Events in Advanced NSCLC Treatment

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.

Detailed description of study

The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lung cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the occurrence and results of serious side effects in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who are treated with an investigational medication. Non-small cell lung cancer is a type of lung cancer that grows and spreads more slowly than small cell lung cancer.

Participants in this study will receive the investigational medication to monitor for any high-grade adverse events, which are serious side effects. The study will collect and analyze data to understand these effects better.

  • Who can participate: Eligibility criteria include adults aged 18 and over with advanced or metastatic non-small cell lung cancer. Additional criteria may apply.
  • Study details: Participants will receive the investigational medication to monitor for serious side effects. An inactive substance, known as a placebo, may be used for comparison; it looks like the investigational medicine but does not contain any active ingredients.
Updated on 19 Feb 2024. Study ID: 1407669234

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team